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Abstract 
We investigated whether chronic intravenous administration of l-carnitine could improve myocardial fatty acid 
imaging in patients on maintenance hemodialysis. We enrolled 72 hemodialysis patients who had impaired myo-
cardial fatty acid imaging and left ventricular dysfunction not based on coronary lesion. l-Carnitine (1,000 mg) was 
intravenously administered after dialysis for 1 year to 36 participants (Carnitine group), while not in the other 36 
participants (Control group). Single-photon emission computed tomography (SPECT) using an iodinated fatty acid 
analogue, BMIPP, was performed. Uptake on SPECT images was graded in 17 segments on a five-point scale (0, nor-
mal; 4, absent) and assessed as BMIPP summed scores. During follow-up, 19 participants were discontinued from the 
study, and 53 participants (65 ± 12 years: 27 carnitine, 26 control) were analyzed. The mean BMIPP summed scores 
1 year after carnitine administration did not differ from that before in the carnitine group, nor from that in the control 
group. However, improved SPECT (Changes in BMIPP summed scores <−20%) was found in 7 (25.9%) participants 
in the carnitine, whereas in 2 (7.7%) in the control group. Multivariate logistic analysis showed the improved SPECT 
was inversely associated with baseline serum albumin levels (1 g/L: odds ratio, 0.669); the cut-off was 35 g/L. Chronic 
intravenous l-carnitine might improve myocardial fatty acid imaging in a selected group of hemodialysis patients 
with hypoalbuminemia.
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Background
Carnitine plays an important role in myocardial fatty acid 
metabolism by transporting long-chain free fatty acids 
(FFA) from the cytoplasm to the matrix of myocardial 
and skeletal muscle mitochondria for β-oxidation. The 
effects of l-carnitine on the cardiovascular complica-
tions of dialysis patients are still controversial, although 
supplementation of l-carnitine in dialysis patients has 
been reported to improve left ventricular (LV) dys-
function and arrhythmia in some studies (Van ES et  al. 
1992; Matsumoto et  al. 2000; Romagnoli et  al. 2002; 
Suzuki et  al. 1982). Sakurabayashi et  al. reported that 
chronic oral administration of l-carnitine to hemodialy-
sis patients did not change myocardial accumulation of 
123I-β-methyliodophenyl pentadecanoic acid (BMIPP), 
an iodinated analogue of free FFA, or LV dimension or 
function, but it increased the washout rate of 123I-BMIPP 
(Sakurabayashi et al. 1999). However, no study has been 
reported regarding the effect of l-carnitine on single-
photon emission computed tomography (SPECT) using 
123I-BMIPP, of which improvement may contribute to 
betterment of LV dysfunction or decrease in cardiac 
death (Nishimura et al. 2006, 2008a, b, 2011, 2014, 2015; 
Moroi et al. 2013). In the present study, we investigated 
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whether chronic intravenous administration of l-carni-
tine could improve impaired myocardial fatty acid imag-
ing in patients on maintenance hemodialysis with LV 
dysfunction not based on obstructive coronary artery 
disease (CAD) or valvular heart diseases.
Methods
Study population
Figure 1 shows a participant flow chart, which proceeded 
at the two dialysis centers associated with the Toujinkai 
Group: Toujinkai Hospital and Toujinkai Clinic. Eligibil-
ity criteria of this study were as follows: (1) Patients on 
chronic hemodialysis with a history of heart failure need-
ing hospitalization (grade IVof New York Heart Associa-
tion) except fluid overload from June 1st, 2012 to May 
31st, 2013; (2) No significant obstructive CAD identified 
by angiography within one year of the study (from June 
1st, 2012 to May 31st, 2013); (3) LV dysfunction evalu-
ated by echocardiography: mildly or moderately reduced 
LV systolic function [left ventricular ejection fraction 
(LVEF) <55%] and/or LV hypertrophy, which indicates 
LV remodeling and lowered LV diastolic function; and 
(4) BMIPP summed scores (SS) ≧4, which was based on 
the results of the B-SAFE study (Moroi et al. 2013). Cri-
teria for exclusion from participation were (1) Moderate 
or worse valvular heart disease; (2) Past history of acute 
or old myocardial infarction and/or coronary revascu-
larization by percutaneous coronary intervention or 
coronary artery bypass grafting. Eighty-seven hemodi-
alysis patients in the Toujinkai Group met the eligibility 
criteria; however, ten patients were excluded based on 
the exclusion criteria, and five patients refused to partic-
ipate this study. Consequently, 72 hemodialysis patients 
were enrolled in this study between June 1st and 30th of 
2013 (40 men and 32 women, mean age: 64 ± 11 years; 
mean dialysis duration: 146 ±  96  months). Simple ran-
domization was performed by assigning the partici-
pants to the carnitine or control group (1:1) in the order 
of enrollment; the person who was not involved in this 
study performed this randomized assignment of par-
ticipants to the two groups. From August 1st, 2013 to 
July 31st, 2014, l-carnitine (l-Cartin® FF, Otsuka Phar-
maceutical Co., Ltd. Tokyo, Japan) was intravenously 
administered after each dialysis session to 36 partici-
pants (Carnitine group), while the other 36 participants 
were not administered l-carnitine (Control group). The 
dose of intravenous administration of l-carnitine was 
uniformly 1,000  mg on each hemodialysis session. The 
Ethics Committee for Human Research of the Toujinkai 
Group approved the study protocol, and all participants 
provided written, informed consent to participate in all 
procedures associated with the study. The study was per-
formed in accordance with the principles of the Decla-
ration of Helsinki, and registered to the ClinicalTrials.
gov (https://www.clinicaltrials.gov/): protocol identifier, 
NCT02322697. 





AnalysisAnalysis (n = 26) Analysis (n = 27)
Lost to follow-up (n = 5)
Discontinued intervention (n = 5)
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Figure 1 Participant flow chart.
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Coronary angiography (CAG)
Experienced interventional cardiologists performed 
quantitative CAG at the Department of Interventional 
Cardiology of Kyoto Second Red Cross Hospital using 
a validated automated edge-detection program (CCIP-
310/W, CATHEX, Tokyo, Japan). Significant coronary 
artery stenosis was defined as stenosis of >50% diameter 
on CAG images.
Radionuclide imaging
All participants underwent resting 123I-BMIPP SPECT 
after fasting for over 6  h on a midweek, non-dialysis 
day within 1 month before the study and at 1 year after 
starting the study. Details of the dual BMIPP SPECT 
procedure are described elsewhere (Nishimura et  al. 
2006, 2008a, b, 2011). The images were divided into 17 
segments for semiquantitative analysis according to the 
standard myocardial segmentation for tomographic heart 
imaging established by the American Heart Association. 
The amount of radioactivity taken up by each segment 
was visually graded and assigned an uptake score of 0 
(normal), 1 (mildly reduced), 2 (moderately reduced), 3 
(severely reduced), or 4 (none). The BMIPP SPECT scores 
for 17 myocardial segments were designated as BMIPP 
SS. The same experienced technician performed all scin-
tigraphic procedures. All BMIPP SPECT images were 
interpreted within one week of the SPECT examination 
by the same two investigators. Both of them interpreted 
SPECT images at the same time without knowledge of 
the identity (name), clinical condition (age, gender, blood 
pressure, presence or absence of diabetes mellitus, car-
diothoracic ratio, dialysis duration and cardiac functions 
evaluated by echocardiography), and laboratory data 
about the participant. The information about the assign-
ment of participants to carnitine or control group was 
not given to these two investigators at the interpretation 
of BMIPP SPECT.
Echocardiography
The participants underwent two-dimensionally guided 
echocardiography using a single ultrasonographic 
recorder (HD11XD, Philips, the Netherlands) on a mid-
week non-dialysis day within 1  month before the study, 
6 months, and 12 months after starting the study. LVEF 
levels were quantified using the biplanar Simpson’s rule, 
and left ventricular mass was measured as recommended 
by the American Society of Echocardiography. Mitral 
early to atrial (E/A) wave velocity ratio was measured as 
an index of LV diastolic function. Left ventricular mass 
was normalized to body surface area, and is described 
herein as left ventricular mass index (LVMI). Criteria for 
LV hypertrophy were an LVMI exceeding 134  g/m2 in 
men or 110 g/m2 in women (Sahn et al. 1978).
Biochemical and hematological determinations
On the first hemodialysis session of the week within 
30 days before starting the study, blood samples (10 ml) 
were obtained from patients who had fasted overnight 
and rested for 10  min. Blood hemoglobin (Hb), plasma 
B-type natriuretic peptide (BNP) concentration, and 
serum concentrations of calcium, inorganic phosphorus, 
albumin, total cholesterol, C-reactive protein (CRP), and 
intact parathyroid hormone were determined. Plasma 
BNP concentrations were measured additionally at 
6 months and 12 months after starting the study. We used 
fasting plasma glucose and fasting plasma insulin con-
centrations to calculate the homeostasis model assess-
ment of insulin resistance (HOMA-IR) as fasting glucose 
concentration (mmol/L) ×  fasting insulin concentration 
(μU/ml)/22.5. Blood samples were collected on the same 
day to measure this and other biochemical and hemato-
logical parameters. Serum concentrations of total, free, 
and acyl carnitine were determined within 30 days before 
the study, and 3, 6, and 12 months after starting the study 
using enzymatic cycling method (SRL, Inc. Tokyo, Japan) 
(Takahashi et  al. 1994). The same erythropoiesis stimu-
lating agent (ESA) (Epoetin beta pegol, C.E.R.A., Chugai 
Pharmaceutical Co., Ltd., Tokyo, Japan) was adminis-
tered to all participants. The ESA resistance index (ERI) 
was determined as the monthly weight-adjusted dose of 
ESA (μg/kg) divided by Hb concentration (g/L). Changes 
in ERI before and 1  year after carnitine administration 
were calculated as follows: (ERI at 1 year after carnitine 
administration–ERI before carnitine administration)/
ERI before carnitine administration × 100 (%). We used 
the dose of ESA and mean blood Hb of the month just 
before starting this study (July, 2013) for calculation of 
ERI before carnitine administration and the dose of ESA 
and mean blood Hb of the last month of this study (July, 
2014) for calculation of ERI after carnitine administra-
tion. Decrease in ERI over 50% was defined as improve-
ment of ERI, whereas increase in ERI over 50% as 
aggravation of ERI.
Statistical analysis
Values are expressed as mean  ±  SD. We compared the 
means of continuous variables using paired or non-paired 
t tests. Categorical data were analyzed using the χ2 test. 
Threshold for the serum albumin concentration for 
changes in BMIPP SS <−20% was defined using receiver-
operating characteristic (ROC) analysis. Any covariates 
that tended to be significant in univariate logistic analy-
ses (P  < 0.1) were assessed by multiple logistic analysis. 
P values <0.05 were considered significant. Individuals 
without knowledge of the participants’ profiles and clini-
cal data performed all statistical analyses. All statistical 
analyses were performed with SAS software version 8.2.
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Results
During the follow-up of 72 participants from Aug 1st, 
2013 to July 31st, 2014, 11 participants were lost for fol-
low-up, and 8 participants were discontinued from this 
study (Figure 1). In the carnitine group (n = 36), 5 partic-
ipants died (2 sudden death, 2 infection, 1 heart failure), 
one participant changed the dialysis center, and three 
participants dropped out from the study (one partici-
pant had severe diarrhea after administering l-carnitine, 
and the other two participants had refused subsequent 
BMIPP SPECT). In the control group (n  =  36), 5 par-
ticipants died (2 sudden death, 2 heart failure, 1 malig-
nancy), and five participants had refused subsequent 
BMIPP SPECT. Consequently, we analyzed the data 
of 53 participants (27 men and 26 women; mean age, 
65 ± 12 years; hemodialysis duration, 149 ± 105 months: 
carnitine group, n = 27; control group, n = 26). Clinical 
baseline characteristics did not differ between the carni-
tine and control groups (Table 1).
Circulating carnitine and BNP concentrations and cardiac 
functions
Compared with the normal ranges of serum carnitine 
concentrations in the laboratory used for measurement in 
this study (total carnitine, 45–91 μmol/L; free carnitine, 
36–74 μmol/L; acyl carnitine, 16–23 μmol/L) (Takahashi 
et  al. 1994), mean baseline serum concentration of free 
carnitine seemed to be lower, and that of acyl carnitine 
higher in the participants. Mean baseline serum concen-
tration of total carnitine did not differ with that of normal 
controls (Table  2). Mean serum concentrations of total, 
free, and acyl carnitine increased at 3 months of intrave-
nous administration of l-carnitine. Mean serum concen-
trations of total and free carnitine were further increased 
at 12 months compared with 3 or 6 months of carnitine 
administration, whereas mean serum concentration of 
acyl carnitine did not differ among 3, 6, or 12 months of 
carnitine administration. Mean values of acyl/free carni-
tine ratio did not differ at 3, 6, or 12 months of carnitine 
administration compared with before administration, but 
decreased at 12  months compared with 3 or 6  months 
(Table 2).
In the control group, mean values of plasma BNP 
concentration, LVEF, and LVMI did not differ among 
before carnitine administration, at 6  months, and at 
12  months of administration (Table  3). In the carnitine 
group, mean values of plasma BNP or LVEF did not alter 
among before, at 6 months, and at 12 months of carnitine 
administration, but LVMI was increased at 12 months of 
carnitine administration compared with before carnitine 
administration. Mean mitral E/A wave velocity ratio did 
not alter among before, at 6, and at 12 months in the con-
trol or carnitine groups (Table 3).
Carnitine and myocardial fatty acid imaging
In the control group, the mean BMIPP SS did not differ 
between before and 12  months after carnitine admin-
istration (18.2  ±  6.0 versus 18.7  ±  6.4, n  =  26) (Fig-
ure 2a). Since we have reported that decrease in BMIPP 
SS <−20% might result in improving cardiac mortality of 
Table 1 Baseline clinical characteristics in  the control 
and cartinine groups







Age, y 64.3 ± 12.9 64.7 ± 12.0 0.892
Male gender, n (%) 14 (53.9) 14 (51.9) 0.887
Dialysis duration, months 141.2 ± 83.8 149.1 ± 105.2 0.763
Smoking, n (%) 9 (34.6) 9 (33.3) 0.923
Alcohol, n (%) 8 (30.8) 8 (29.6) 0.930
Diabetes mellitus, n (%) 13 (50.0) 14 (51.9) 0.895
Systolic blood pressure before 
dialysis, mm Hg
138.0 ± 12.1 134.0 ± 18.8 0.360
Diastolic blood pressure before 
dialysis, mm Hg
73.4 ± 10.6 70.5 ± 14.7 0.408
Body mass index, kg/m2 21.2 ± 4.5 22.9 ± 4.1 0.170
Cardiothoracic ratio, % 53.1 ± 5.8 53.3 ± 4.9 0.922
Left ventricular ejection fraction, 
%
52.2 ± 11.9 53.2 ± 11.9 0.696
Left ventricular mass index, g/m2 126.6 ± 24.8 126.4 ± 24.1 0.962
Mitral early to atrial (E/A) wave 
velocity ratio
1.2 ± 0.6 1.1 ± 0.6 0.875
Blood hemoglobin, g/L 106.8 ± 10.8 106.1 ± 9.0 0.800
Serum albumin, g/L 37.8 ± 2.9 37.9 ± 3.4 0892
Serum calcium, mmol/L 2.2 ± 0.1 2.2 ± 0.1 0.451
Serum inorganic phosphorus, 
mmol/L
1.6 ± 0.4 1.6 ± 0.3 0.810
Serum total cholesterol, mmol/L 4.1 ± 0.6 3.9 ± 1.1 0.515
Serum ferritin, pmol/L 273.9 ± 185.8 281.8 ± 197.7 0.859
Serum intact parathyroid hor-
mone, ng/L
176.1 ± 99.3 133.4 ± 106.0 0.136
Serum C-reactive protein, mg/L 2.5 ± 2.2 2.2 ± 2.6 0.635
Plasma B-type natriuretic peptide, 
ng/L
291.2 ± 174.6 249.2 ± 229.1 0.457
HOMA-IR, mmol/L・μU/ml 5.9 ± 1.9 5.3 ± 2.3 0.294
BMIPP summed score 18.2 ± 6.0 18.9 ± 11.3 0.794
Medications
α1 blockers, n (%) 2 (7.7) 3 (11.1) 0.677
β blockers, n (%) 17 (65.4) 17 (63.0) 0.858
Calcium blockers, n (%) 7 (26.9) 7 (25.9) 0.936
RAS inhibitors, n (%) 8 (30.8) 9 (33.3) 0.845
Nitrates, n (%) 3 (11.5) 3 (11.1) 0.962
Antiplatelet drugs, n (%) 16 (61.5) 18 (66.7) 0.704
Anticoagulation drugs, n (%) 3 (11.5) 5 (18.5) 0.487
Statins, n (%) 7 (26.9) 7 (25.9) 0.936
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hemodialysis patients in our recent studies (Nishimura 
et al. 2014, 2015), we subdivided participants of the car-
nitine and control groups into the following three sub-
groups according to the changes in BMIPP SS: improved 
subgroup, changes in BMIPP SS <−20%; deteriorated 
subgroup, changes in BMIPP SS >20%; unchanged sub-
group, changes in BMIPP SS  ±  20%. In the control 
group (n = 26), 2 (7.7%), 4 (15.4%), and 20 (76.9%) par-
ticipants were allocated to the improved, deteriorated, 
and unchanged subgroup, respectively. In the carnitine 
group, the mean BMIPP SS also did not differ between 
before and 12  months after carnitine administration 
(18.9 ± 11.3 versus 20.7 ± 13.5, n = 27) (Figure 2b). In 
the carnitine group (n  =  27), 7 (25.9%), 8 (29.6%), and 
12 (44.5%) participants were allocated to the improved, 
deteriorated, and unchanged subgroup, respectively. Fig-
ure  3 shows one of the improved cases in the carnitine 
group. The allocation to improved subgroup was greater 
(P  =  0.025) in the carnitine than in the control group, 
whereas the allocation to deteriorated subgroup did not 
differ between the two groups (P = 0.2).
Differences in baseline clinical or laboratory data 
and cardiac function by changes in BMIPP SS
The baseline mean LVEF was lower in the improved 
subgroup than in the deteriorated subgroup, and the 
baseline mean values of serum albumin and total cho-
lesterol concentrations were lower in the improved sub-
group than in the unchanged subgroup (Table 4). Mean 
serum baseline concentrations of total, free, or acyl car-
nitine and acyl/free carnitine ratio did not differ among 
the three subgroups (Table 4). In addition, mean serum 
carnitine concentrations and acyl/free carnitine ratio 
1  year after l-carnitine administration did not differ 
among the subgroups (total carnitine: changes in BMIPP 
SS <−20%, 464.4  ±  156.5  μmol/L, changes in BMIPP 
SS ±  20%, 441.3 ±  85.7 μmol/L, changes in BMIPP SS 
>20%, 420.3  ±  70.5  μmol/L; free carnitine: SS <−20%, 
286.4 ±  93.6 μmol/L, SS ±  20%, 255.8 ±  45.9 μmol/L, 
SS >20%, 259.9 ± 39.7 μmol/L; acyl carnitine: SS<−20%, 
178.1 ±  75.0 μmol/L, SS ±  20%, 185.5 ±  45.3 μmol/L, 
SS >20%, 160.4 ± 37.1 μmol/L; acyl/free carnitine ratio: 
SS <−20%, 0.62 ± 0.15, SS ± 20%, 0.72 ± 0.12, SS >20%, 
0.62  ±  0.11). Mean changes in LVEF after administra-
tion of l-carnitine were better in the improved sub-
group (28.3  ±  15.9%) compared with the unchanged 
(3.5 ± 23.7%) or deteriorated subgroup (−13.6 ± 13.1%) 
(Figure 4).
Table 2 Changes in  serum concentrations of  carnitine 
after intravenous administratin of l-carnitine
* P < 0.01 versus before; †P < 0.05 versus 3 months; ††P < 0.01 versus 3 months; 
∫P < 0.05 versus 6 months; ∬P < 0.01 versus 6 months.


















0.70 ± 0.14 0.72 ± 0.14 0.73 ± 0.17 0.67 ± 0.1†∫
Table 3 Changes in  plasma B-type natriuretic peptide 
concentrations and left ventricular function in the control 
and carnitine group
* P < 0.01 versus before.
Before 6 months 12 months
Control group (n = 26)
 Plasma B-type natriu-
retic peptide, ng/L
291.2 ± 174.6 285.6 ± 165.9 310.1 ± 168.8
 Left ventricular ejection 
fraction, %
52.2 ± 4.8 52.0 ± 5.7 51.9 ± 6.0
 Left ventricular mass 
index, g/m2
126.4 ± 24.1 126.3 ± 25.1 126.5± 23.8
 Mitral early to atrial (E/A) 
wave velocity ratio
1.1 ± 0.6 1.1 ± 0.7 1.1 ± 0.6
Carnitine group (n = 27)
 Plasma B-type natriu-
retic peptide, ng/L
249.2 ± 229.1 274.2 ± 213.2 360.2 ± 440.3
 Left ventricular ejection 
fraction, %
53.2 ± 11.9 54.0 ± 11.7 53.7 ± 9.5
 Left ventricular mass 
index, g/m2
126.6 ± 24.8 138.0 ± 39.3 140.9 ± 34.8*
 Mitral early to atrial (E/A) 
wave velocity ratio










































Figure 2 Changes in BMIPP summed scores before and 12 months 
after carnitine administration. a Control group, n = 26. b Carnitine 
group, n = 27.
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Factors related with improvement in BMIPP SPECT 
after carnitine administration
In an univariate logistic analysis, changes in BMIPP SS 
<−20% (Improved BMIPP SPECT) was significantly 
associated with baseline serum concentrations of albu-
min, total cholesterol, and CRP, and tended to be associ-
ated with baseline LVEF and serum ferritin concentration 
(Table  5). Mean ERI did not differ between before and 
after carnitine administration (0.02  ±  0.02 versus 
0.02 ± 0.02, P = 0.860). Improvement of ERI was found 
in 10 of 27 patients (37.0%), and aggravation of ERI in 
5 of 27 patients (18.5%). Changes in BMIPP SS did not 
correlate with changes in ERI (r  =  -0.061, P  =  0.764), 
and changes in ERI were not associated with decrease 
in BMIPP SS <−20% (10%: Odds ratio, 0.999; 95% confi-
dence interval, 0.996–1.002; P = 0.449). In a multivariate 
logistic analysis among the factors of P < 0.1 in an uni-
variate analysis, decrease in BMIPP SS <−20% was asso-
ciated with baseline serum albumin concentration (1 g/L: 
odds ratio, 0.669; 95% confidence interval, 0.456–0.980; 
P = 0.039). In ROC analysis, the cut-off of baseline serum 
albumin concentration for decrease in BMIPP SS <−20% 
was 35  g/L (area under the curve: 0.789). Mean serum 
albumin concentration one year after administration of 
l-carnitine tended to be higher than that before l-car-
nitine administration in patients with changes in BMIPP 
SS <−20% (37.9 ± 1.2 versus 35.4 ± 2.8 g/L, P = 0.075, 
n  =  7), but did not differ in patients with changes in 
BMIPP SS  ±  20% (38.3  ±  1.8 versus 39.4  ±  2.9  g/L, 
P =  0.162, n =  12) or those with changes in BMIPP SS 
>20% (36.4 ± 3.5 versus 37.9 ± 3.5 g/L, P = 0.142, n = 8).
Discussion
The present study showed that chronic intravenous 
administration of l-carnitine did not significantly affect 
mean BMIPP SS evaluated by SPECT in hemodialysis 
patients with LV dysfunction, although circulating lev-
els of l-carnitine increased almost six-fold at 3 month of 
administration. When we divided the participants of the 
carnitine group into the three subgroups according to the 
increase or decrease in BMIPP SS, 25.9% were allocated 
to the improved subgroup, whereas 29.6% were allocated 
to the deteriorated subgroup. Improved uptake of BMIPP 
in SPECT after l-carnitine administration was associated 
with betterment of LVEF. Responders and non-respond-
ers may exist among hemodialysis patients regarding the 
effect of l-carnitine on myocardial fatty acid imaging.
Over 70% of the energy required by the normal myo-
cardium under aerobic conditions derives from metabo-
lism of FFA. Under hypoxic or ischemic conditions, FFA 
metabolism is believed to be suppressed and replaced 
by glucose metabolism, which requires less oxygen con-
sumption. 123I-BMIPP is a branched FFA analogue char-
acterized by resistance to β-oxidation. The metabolism 
and kinetics of BMIPP in myocardial cells are deter-
mined by the following factors: (1) Incorporation from 
the blood into cardiac muscle cells via the CD36-positive 
FFA binding protein on the myocardial cell membrane; 
(2) Back diffusion from myocardial cells into the blood 
that occurs immediately after incorporation; (3) Intra-
cardiac concentrations of adenosine triphosphate (ATP), 
which is required for acylation of BMIPP; (4) Accumula-
tion of acyl BMIPP in the lipid pool; and (5) Metabolism 
Figure 3 BMIPP SPECT images from a participant who showed improvement after administration of l-carnitine: a 70-year-old non-diabetic 
woman whose dialysis duration was 22 years. BMIPP summed scores were 28 before administration of l-carnitine (a) and 12 after administration of 
l-carnitine for one year (b). Left ventricular ejection fraction evaluated by echocardiography also improved, from 43 to 62% after administration of 
l-carnitine. Her baseline serum albumin concentration was 34 g/L.
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to ρ-iodophenyl acetic acid via α- or β-oxidation in 
mitochondria. Of intracoronary-administered BMIPP 
in canine myocardium, uptake into myocardial cells was 
74%, and retention of acyl BMIPP was 65.3%, whereas 
metabolism via α- or β-oxidation was only 8.7%. Intracar-
diac ATP and accumulation in the lipid pool are believed 
to be significantly associated with early cardiac imaging 
by BMIPP SPECT (Yamamichi et al. 1995; Tanaka et al. 
1997; Kawasaki et al. 1999; Fujibayashi et al. 1990, 1996; 
Hosokawa et al. 1997).
Experimental administration of etomoxir, a carni-
tine palmitoyltransferase I inhibitor, to dogs did not 
affect retention of 123I-BMIPP in the heart (Hosokawa 
et  al. 1996). Since only a small fraction of BMIPP is 
Table 4 Differences in baseline characteristics among the subgroups of carnitine administration
SS summed score, HOMA-IR the homeostasis model assessment index of insulin resistance, RAS renin-angiotensin system.
*P < 0.05 versus the subgroup of BMIPP SS changes between ±20%.
† P < 0.05 versus the subgroup of BMIPP SS changes >20%.
BMIPP SS changes <-20%
(n=7)
BMIPP SS changes between ±20%
(n=12)
BMIPP SS changes >+20%
(n=8)
Age, y 63.9 ± 11.5 63.3 ± 11.3 64.8 ± 12.0
Male gender, n (%) 2 (28.6) 7 (58.3) 5 (62.5)
Dialysis duration, months 143.3 ± 89.1 170.6 ± 112.7 122.0 ± 112.6
Smoking, n (%) 1 (14.3) 3 (25.0) 5 (62.5)
Alcohol, n (%) 1 (14.3) 3 (25.0) 4 (50.0)
Diabetes mellitus, n (%) 4 (57.1) 6 (50.0) 4 (50.0)
Systolic blood pressure before dialysis, mm Hg 135.3 ± 19.4 134.8 ± 19.4 134.0 ± 18.8
Diastolic blood pressure before dialysis, mm Hg 70.1 ± 14.1 68.9 ± 16.1 70.5 ± 14.7
Body mass index, kg/m2 21.0 ± 4.5 24.0 ± 4.2 22.9 ± 4.1
Cardiothoracic ratio, % 53.9 ± 5.7 52.0 ± 4.5 54.7 ± 4.7
Left ventricular ejection fraction, % 46.0 ± 8.8† 52.3 ± 14.6 60.9 ± 3.1
Left ventricular mass index, g/m2 126.0 ± 35.0 122.4 ± 25.7 133.5 ± 11.0
Mitral early to atrial (E/A) wave velocity ratio 1.1 ± 0.6 1.1 ± 0.7 1.0 ± 0.4
Blood hemoglobin, g/L 104.9 ± 6.5 109.0 ± 10.8 103.0 ± 7.5
Serum albumin, g/L 35.4 ± 2.8* 39.4 ± 2.9 37.9 ± 3.5
Serum calcium, mmol/L 2.2 ± 0.2 2.2 ± 0.1 2.2 ± 0.2
Serum inorganic phosphorus, mmol/L 1.6 ± 0.2 1.5 ± 0.4 1.6 ± 0.3
Serum total cholesterol, mmol/L 3.1 ± 1.0* 4.4 ± 0.9 3.8 ± 0.8
Serum ferritin, pmol/L 403.1 ± 198.2 269.6 ± 253.0 274.1 ± 155.7
Serum intact parathyroid hormone, ng/L 78.1 ± 59.9 122.1 ± 15.9 198.6 ± 96.9
Serum C-reactive protein, mg/L 4.0 ± 3.7 1.3 ± 1.1 2.0 ± 2.6
Plasma B-type natriuretic peptide, ng/L 289.2 ± 245.4 205.6 ± 229.2 279.5 ± 234.1
HOMA-IR, mmol/L・μU/ml 5.8 ± 2.6 5.4 ± 2.4 4.6 ± 2.0
BMIPP summed score 15.1 ± 8.2 22.8 ± 13.2 16.3 ± 9.9
Total carnitine, μmol/L 59.3 ± 52.7 58.9 ± 41.1 62.3 ± 59.0
Free carnitine, μmol/L 36.9 ± 38.6 33.7 ± 23.3 44.1 ± 57.1
Acyl carnitine, μmol/L 22.4 ± 14.4 25.1 ± 18.0 26.2 ± 31.3
Acyl/ free carnitine ratio 0.72 ± 0.15 0.73 ± 0.15 0.64 ± 0.11
Medications
α1 blockers, n (%) 1 (14.3) 0 (0) 2 (25.0)
β blockers, n (%) 5 (71.4) 6 (50.0) 6 (75.0)
Calcium blockers, n (%) 3 (42.9) 2 (16.7) 2 (25.0)
RAS inhibitors, n (%) 3 (42.9) 2 (16.7) 4 (50.0)
Nitrates, n (%) 1 (14.3) 2 (16.7) 0 (0)
Antiplatelet drugs, n (%) 5 (71.4) 9 (75.0) 4 (50.0)
Anticoagulation drugs, n (%) 1 (14.3) 1 (8.3) 3 (37.5)
Statins, n (%) 1 (14.3) 4 (33.3) 2 (25.0)
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metabolized via α- or β-oxidation in mitochondria 
as described above, other mechanisms of l-carnitine 
besides accelerating BMIPP metabolism would be 
involved in improving fatty acid imaging in hemodialysis 
patients. Impaired fatty acid metabolism and consequent 
accumulation of acyl CoA (Coenzyme A) are character-
istic of renal failure (Wanner and Hörl 1988). Accumu-
lated acyl CoAs inhibit glucose uptake by disruption of 
the intracellular signaling cascade that moves the GLUT4 
transporter from its intracellular location to the surface 
of the myocardial membrane (Dresner et  al. 1999; Grif-
fin et  al. 1999), and also inhibit enzymes important in 
glucose metabolism such as pyruvate dehydrogenase 
(Moore et al. 1992; Sugden et al. 1995): accumulated acyl 
CoAs thereby enhance insulin resistance. In our previ-
ous study, impaired fatty acid metabolism evaluated by 
BMIPP SPECT was in proportion to HOMA-IR in dia-
betic and nondiabetic hemodialysis patients (Nishimura 
et  al. 2006). This inhibition of acyl CoAs to glucose 
metabolism is reportedly suppressed by administration of 
l-carnitine in hemodialysis patients (Günal et  al. 1999). 
l-Carnitine reduces the concentration of acyl CoA esters 
and improves efflux of excess acyl carnitine from the 
mitochondria and myocardium via an exchange trans-
port system (Kobayashi and Fujiwara 1994). By reduc-
ing acyl CoAs from the mitochondria, l-carnitine may 
enhance glucose oxidation and increase myocardial syn-
thesis of ATP in spite of impaired fatty acid metabolism.
In this study, baseline serum albumin concentration 
below 35  g/L was the potent predictor for improve-

































Figure 4 Differences in percent changes in mean left ventricular 
ejection fraction (LVEF) among subgroups divided by changes 
in BMIPP summed scores (SS) after intravenous administration of 
l-carnitine for 1 year.
Table 5 Univariate logistic analysis for  BMIPP SS changes 
<-20%
SS summed score, CI confidence interval, HOMA-IR the homeostasis model, RAS 
renin-angiotensin system.
Odds ratio 95% CI P
Age (1 y) 0.991 0.921–1.067 0.811
Male gender 0.267 0.041–1.727 0.166
Dialysis duration (1month) 0.999 0.991–1.008 0.862
Smoking 0.250 0.025–2.489 0.237
Alcohol 0.310 0.031–3.111 0.319
Diabetes mellitus 1.333 0.235–7.556 0.745
Systolic blood pressure before 
dialysis (1 mm Hg)
1.005 0.959–1.053 0.826
Diastolic blood pressure before 
dialysis (1 mm Hg)
0.998 0.940–1.059 0.942
Body mass index (1 kg/m2) 0.824 0.629–1.079 0.159
Cardiothoracic ratio (1%) 1.036 0.864–1.243 0.700
Left ventricular ejection fraction 
(1%)
0.935 0.867–1.008 0.081
Left ventricular mass index, (1 g/
m2)
0.999 0.964–1.034 0.938
Mitral early to atrial (E/A) wave 
velocity ratio (1)
1.289 0.310–5.354 0.727
Blood hemoglobin (1 g/L) 0.801 0.302–2.121 0.655
Serum albumin (1 g/L) 0.669 0.456–0.980 0.039
Serum calcium (1 mmol/L) 0.895 0.002–437.4 0.972






Serum ferritin (1 pmol/L) 1.004 0.999–1.009 0.097
Serum intact parathyroid hormone 
(1 ng/L)
0.991 0.981–1.002 0.120
Serum C-reactive protein (1 mg/L) 1.421 1.004–2.010 0.047
Plasma B-type natriuretic peptide 
(1 ng/L)
1.001 0.997–1,005 0.587
HOMA-IR (1 mmol/L・μU/ml) 1.171 0.790–1.738 0.432
Serum total carnitine (1 μmol/L) 0.999 0.983–1.014 0.870
Serum free carnitine (1 μmol/L) 0.999 0.976–1.023 0.952
Serum acyl carnitine (1 μmol/L) 0.992 0.946–1.040 0.732
Acyl/free carnitine ratio (1) 3.937 0.006–2774.282 0.682
BMIPP summed score (1) 0.952 0.866–1.047 0.311
Medications
α1 blockers 1.500 0.115–19.640 0.757
β blockers 1.667 0.257–10.792 0.592
Calcium blockers 3.000 0.469–19.176 0.246
RAS inhibitors 1.750 0.296–10.340 0.537
Nitrates 1.500 0.115–19.640 0.757
Antiplatelet drugs 1.346 0.205–8.819 0.757
Anticoagulation drugs 0.667 0.061–7.230 0.739
Statins 0.389 0.038–3.970 0.426
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Serum albumin concentration basically correlates with 
body protein stores, and serum albumin concentration 
below 38 g/L suggests a diagnosis of protein-energy wast-
ing (Fouque et al. 2011), which is defined as a pathological 
state in which there is a continuous decrease or wasting 
of both protein deposits and energy reserves. Impaired 
protein anabolism, as well as insulin resistance, is one of 
the metabolic alterations in patients with end-stage kid-
ney disease (Avesani et al. 2011). In animal studies, l-car-
nitine administration directly suppressed branched-chain 
alpha-keto acid dehydrogenase activity; this would lead to 
increase in intracellular levels of branched-chain amino 
acids (Owen et  al. 2001). Branched-chain amino acids 
like leucine, valine, and isoleucine play an important 
role in regulation of body protein turnover (Nakashima 
et al. 2005; Kimball and Jefferson 2006). Biolo et al. (2008) 
reported that l-carnitine supplementation was associ-
ated with lower rates of leucine oxidation and appear-
ance from proteolysis during the insulin clamp studies 
than after placebo supplementation. In the present study, 
mean serum albumin concentration in the subgroup of 
changes in BMIPP SS <−20% was higher after l-carni-
tine administration than before, whereas it did not differ 
between before and after l-carnitine administration in 
other subgroups. The results of this study indicate that 
the state of protein-energy wasting may be involved in 
the mechanism of impaired myocardial fatty acid imag-
ing and that protein-sparing effects of l-carnitine is likely 
to play a role in improving impaired BMIPP SPECT in 
this population. Further investigation is needed to clarify 
this important point.
This study has several limitations. We used CAG to 
confirm the presence of suspected myocardial ischemia 
in the participants. “Without significant obstructive 
CAD” does not necessarily mean that the epicardial 
coronary arteries are normal. Since histopathological 
and intravascular ultrasound studies have demonstrated 
the propensity of angiography to underestimate lesional 
severity (Porter et al. 1993), we cannot exclude the pos-
sibility that some angiographically non-significant lesions 
were flow-limiting. During the follow-up of 72 partici-
pants, 11 participants were lost for follow-up, and 8 par-
ticipants were discontinued from this study; this high 
rate of exclusion of participants from the analysis would 
be a potential source of bias in this study. Since our study 
was a small, non-blinded, open-labeled trial, it would be 
difficult to capture a significant effect of l-carnitine and 
to precisely perform a multivariate analysis. A large, ran-
domized trial is needed to clarify the effects of l-carni-
tine on impaired myocardial fatty acid imaging.
In conclusion, long-term intravenous administration 
of l-carnitine did not improve myocardial fatty acid 
imaging evaluated by BMIPP SPECT in all hemodialysis 
patients with LV dysfunction. However, improvement in 
BMIPP SPECT was found in almost one-forth of the par-
ticipants. Hypoalbuminemia below 35  g/L could be one 
of the clinical parameters to select hemodialysis patients 
for administration of l-carnitine to improve fatty acid 
metabolism and cardiac dysfunction. Intravenous l-car-
nitine might be an alternative way to treat uremic car-
diomyopathy in addition to conventional therapies in a 
selected group of hemodialysis patients.
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